Coxsackieviruses Questions & Answers

1. Tariq N, Kyriakopoulos C. Group B Coxsackie Virus. 2022 Jan. [QxMD MEDLINE Link]. [Full Text].

2. Nikonov OS, Chernykh ES, Garber MB, Nikonova EY. Enteroviruses: Classification, Diseases They Cause, and Approaches to Development of Antiviral Drugs. Biochemistry (Mosc). December 2017. (82)13:1615-1631.

3. Issacs S, Foskett D, Maxwell A, Ward E, Faulkner C, Luo J, et al. Viruses and type-1 diabetes: from enteroviruses to the virome. Microorganisms. 2021. 9:

4. Tyring S. Hand foot and mouth disease: enteroviral load and disease severity. EBioMedicine. 2020. 62:

5. Elrick M, Pekosz A, Duggal P. Enterovirus D68 molecular and cellular biology and pathogenesis. Journal Biol Chem. 2021. 296:

6. Olsen S, Winn A, Budd A, Prill M, Steel J, Midgley, et al. Changes in influenza and other respiratory virus activity during the COVID-19 pandemic-United States, 2020-2021. Morbidity and Mortality Weekly Report. July 23, 2021. 70:1013-1019.

7. Brotons P, Jordan I, Bassat Q, Henares D, Fernandez de Sevilla M, Ajanovic S, et al. The positive rhinovirus/enterovirus detection and SARS-CoV-2 persistence beyond the acute infection phase: an intra-household surveillance study. Viruses. 2021. 13:

8. Olsen SJ, Winn AK, Budd AP, et al. Changes in Influenza and Other Respiratory Virus Activity During the COVID-19 Pandemic — United States, 2020–2021. MMWR Morb Mortal Wkly Rep. July 23, 2021. 70:1013-1019. [Full Text].

9. Chow Eric J, Uyeki Timothy M, Chu Helen Y. The effects of the COVID-19 pandemic on community respiratory virus activity. Nat Rev Microbiol. October 17, 2022. 1-16. [Full Text].

10. Rotbart HA, McCracken GH Jr, Whitley RJ, Modlin JF, Cascino M, Shah S, et al. Clinical significance of enteroviruses in serious summer febrile illnesses of children. Pediatr Infect Dis J. 1999. 10:869-74.

11. Kogon A, Spigland I, Frothingham TE, Elveback L, Williams C, Hall CE, et al. The virus watch program: a continuing surveillance of viral infections in metropolitan New York families. VII. Observations on viral excretion, seroimmunity, intrafamilial spread and illness association in coxsackie and echovirus infections. Am J Epidemiol. Jan 1968. 1:51-61.

12. Posnakoglou L, Tatsi E, Chatzichristou P, Siahanidou T, Kanaka-Gantenbein C, Syriopoulou V, et al. Molecular epidemiology of enterovirus in children with central nervous system infections. Viruses. 2021. 13:

13. Oikarinen S, Krogvold L, Edwin B, Buanes T, Korsgren O, Laiho J, et al. Characterisation of enterovirus RNA detected in the pancreas and other specimens of live patients with newly diagnosed type 1 diabetes in the DiViD study. Diabetologia. 2021 Nov. 64:2491-2501.

14. Nekoua MP, Alidjinou EK, Hober D. Persistent coxsackievirus B infection and pathogenesis of type 1 diabetes mellitus. Nat Rev Endocrinol. June 1, 2022. 18(8):503-516. [Full Text].

15. Alhazmi A, Nekoua MP, Michaux H, Sane F, Halouani A, Engelmann I, et al. Effect of Coxsackievirus B4 Infection on the Thymus: Elucidating Its Role in the Pathogenesis of Type 1 Diabetes. Microorganisms. May 29, 2021. 9(6):1177. [Full Text].

16. Horsten H. Eczema Coxsackium caused by Coxsackievirus A6. Pediatric Dermatology. 2016. 33:e230-e231.

17. Perez V, Melnick L, Whittier S, Dayan P, Garzon M, Morel K, et al. The use of respiratory pathogen panel nasal polymerase chain reaction testing in predicting cutaneous enteroviral infections in the pediatric population. Pediatric Dermatology. 2021. 38:602-605.

18. Baggen J, Hurdiss DL, Zocher G, Mistry N, Roberts RW, Slager JJ, et al. Role of enhanced receptor engagement in the evolution of a pandemic acute hemorrhagic conjunctivitis virus. Proc Natl Acad Sci U S A. January 9, 2018. 115(2):397-402.

19. Zheng M, Wang H, Tang J, He Y, Xiong T, Li W, et al. Clinical characteristics of severe neonatal enterovirus infection: a systematic review. BMC Pediatrics. 2021. 21:127.

20. Claassen J, Mayer SA, Kowalski RG, Emerson RG, Hirsch LJ. Detection of electrographic seizures with continuous EEG monitoring in critically ill patients. Neurology. May 25, 2004. 10:1743-8. [Full Text].

21. Mohamed Saied Abdelgawad, Abd El-Aziz El-Nekidy, Rania A.M. Abouyoussef, Amr El-Fatary. MRI findings of enteroviral encephalomyelitis. The Egyptian Journal of Radiology and Nuclear Medicine. 2016. 47:1031-6.

22. Kotanidis CP, Bazmpani MA, Haidich AB, Karvounis C, Antoniades C, Karamitsos TD. Diagnostic Accuracy of Cardiovascular Magnetic Resonance in Acute Myocarditis: A Systematic Review and Meta-Analysis. JACC Cardiovasc Imaging. November 2018. 11:1583-1590.

23. Anasir M, Zarif F, Poh C. Antivirals blocking entry of enteroviruses and therapeutic potential. Journal of Biomedical Science. 2021. 28:

24. Pevear DC, Tull TM, Seipel ME, Groarke JM. Activity of pleconaril against enteroviruses. Antimicrob Agents Chemother. September 1999. 43(9):2109-15. [Full Text].

25. Rotbart HA, Webster AD; Pleconaril Treatment Registry Group. Treatment of potentially life-threatening enterovirus infections with pleconaril. Clin Infect Dis. January 15, 2001. 32(2):228-35. [Full Text].

26. Desmond RA, Accortt NA, Talley L, Villano SA, Soong SJ, Whitley RJ. Enteroviral meningitis: natural history and outcome of pleconaril therapy. Antimicrob Agents Chemother. July 2006. 50(7):2409-14. [Full Text].

27. Wagner JN, Leibetseder A, Troescher A, Panholzer J, von Oertzen TJ. Characteristics and therapy of enteroviral encephalitis: case report and systematic literature review. Int J Infect Dis. December 2021. 113:93-102.

28. Schiff GM, Sherwood JR. Clinical activity of pleconaril in an experimentally induced coxsackievirus A21 respiratory infection. J Infect Dis. 2000 Jan. 181(1):20-6. [QxMD MEDLINE Link].

29. Brunetti L, DeSantis ER. Treatment of viral myocarditis caused by coxsackievirus B. Am J Health Syst Pharm. 2008 Jan 15. 65(2):132-7. [QxMD MEDLINE Link].

30. Yue-Chun L, LiSha G, Jiang-Hua R, Peng-Lin Y, Jia-Feng L, Ji-Fei T, et al. Protective effects of carvedilol in murine model with the coxsackievirus B3-induced viral myocarditis. J Cardiovas Pharmacol. Jan/2008. 51:92-98. [QxMD MEDLINE Link].

31. Shi L, Xiong H, He J, et al. Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo. Arch Virol. 2007. 152(8):1447-55. [QxMD MEDLINE Link].

32. Cheng D, Chiu YW, Huang SW, Lien YY, Chang CL, Tsai HP, et al. Genetic and Cross Neutralization Analyses of Coxsackievirus A16 Circulating in Taiwan from 1998 to 2021 Suggest Dominant Genotype B1 can Serve as Vaccine Candidate. Viruses. October 20, 2022. 14(10):2306. [Full Text].

33. Mao QY, Wang Y, Bian L, Xu M, Liang Z. EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD). Expert Rev Vaccines. January 14, 2016. 15(5):599-606. [Full Text].

34. PROtocol for Coxsackievirus VaccinE in Healthy VoluNTteers (PROVENT). ClinicalTrials.gov. Available at https://clinicaltrials.gov/ct2/show/NCT04690426. December 30, 2020; Accessed: July 25, 2022.

35. CDC. Non-Polio Enterovirus: Outbreaks & Surveillance. CDC. Available at https://www.cdc.gov/non-polio-enterovirus/outbreaks-surveillance.html. November 14, 2018; Accessed: December 6, 2019.

36. CDC. Non-Polio Enterovirus: For Health Care Professionals. CDC. Available at https://www.cdc.gov/non-polio-enterovirus/hcp.html. November 14, 2018; Accessed: December 6, 2019.

37. CDC. Acute Flaccid Myelitis: AFM Investigation. CDC. Available at https://www.cdc.gov/acute-flaccid-myelitis/afm-investigation.html. November 4, 2019; Accessed: December 6, 2019.

Eric Wu, MD Academic Hospitalist, Michael E DeBakey VA Medical Center; Assistant Professor, Baylor College of Medicine

Disclosure: Nothing to disclose.

Rajeev Balchandani, MD Assistant Professor of Medicine, Baylor College of Medicine; Hospitalist Physician, Medicine Care Line, Michael E DeBakey VA Medical Center

Rajeev Balchandani, MD is a member of the following medical societies: American Medical Association, Society of Hospital Medicine

Disclosure: Nothing to disclose.

Prathit A Kulkarni, MD Assistant Professor, Department of Medicine, Section of Infectious Diseases, Associate Program Director, Infectious Diseases Fellowship Program, Baylor College of Medicine; Assistant Chief of Medicine, Medical Care Line, Associate Site Director, Internal Medicine Residency Program, Michael E DeBakey Veterans Affairs Medical Center

Prathit A Kulkarni, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, Gold Humanism Honor Society, Infectious Diseases Society of America, Society for Healthcare Epidemiology of America

Disclosure: Received research grant from: Vessel Health, Inc.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

John W King, MD Professor of Medicine, Chief, Section of Infectious Diseases, Director, Viral Therapeutics Clinics for Hepatitis, Louisiana State University School of Medicine in Shreveport; Consultant in Infectious Diseases, Overton Brooks Veterans Affairs Medical Center

John W King, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians, American Federation for Medical Research, American Society for Microbiology, Association of Subspecialty Professors, Infectious Diseases Society of America, Sigma Xi, The Scientific Research Honor Society

Disclosure: Nothing to disclose.

Michael Stuart Bronze, MD David Ross Boyd Professor and Chairman, Department of Medicine, Stewart G Wolf Endowed Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center; Master of the American College of Physicians; Fellow, Infectious Diseases Society of America; Fellow of the Royal College of Physicians, London

Michael Stuart Bronze, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American Medical Association, Association of Professors of Medicine, Infectious Diseases Society of America, Oklahoma State Medical Association, Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

Maria D Mileno, MD Associate Professor of Medicine, Division of Infectious Diseases, The Warren Alpert Medical School of Brown University

Maria D Mileno, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, International Society of Travel Medicine, Sigma Xi, The Scientific Research Honor Society

Disclosure: Nothing to disclose.

Martha L Muller, MD, MPH Professor of Pediatrics, Division of Infectious Diseases, University of New Mexico School of Medicine

Disclosure: Nothing to disclose.

Mashiul H Chowdhury, MD Assistant Professor, Department of Medicine, Division of Infectious Disease, Program Director, Infectious Disease Fellowship, Director, TravelHealth Center, Drexel University College of Medicine

Disclosure: Nothing to disclose.

Nhat M Doan, MD Fellow, Department of Internal Medicine, Division of Infectious Diseases, Washington Hospital Center

Disclosure: Nothing to disclose.

Parul Kaushik, MD, MPH Fellow, Department of Medicine, Division of Infectious Disease, Drexel University College of Medicine

Disclosure: Nothing to disclose.

Michael Rajnik, MD Associate Professor, Department of Pediatrics, Program Director, Pediatric Infectious Disease Fellowship Program, Uniformed Services University of the Health Sciences

Michael Rajnik is a member of the following medical societies: American Academy of Pediatrics, Armed Forces Infectious Disease Society, Infectious Diseases Society of America, and Pediatric Infectious Diseases Society.

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article